Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 6/20 | 0.39 |
| ▸ | REN | P00797 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22815872 | 0.87 | HCRTR2 (0.41) | RAB9APOLBL3MBTL1 | |
| SCHEMBL12069452 | 0.86 | RAB9A (0.38) | RAB9APOLBL3MBTL1ACEREN | |
| SCHEMBL23142701 | 0.84 | RAB9A (0.39) | RAB9APOLBL3MBTL1DPP4 | |
| SCHEMBL23569770 | 0.84 | L3MBTL1 (0.39) | RAB9APOLBL3MBTL1ACEREN | |
| SCHEMBL28620181 | 0.83 | POLB (0.41) | RAB9APOLBL3MBTL1ACEREN | |
| SCHEMBL6119785 | 0.83 | POLB (0.41) | RAB9APOLBL3MBTL1ACEREN | |
| SCHEMBL23142700 | 0.83 | HCRTR2 (0.46) | RAB9APOLBL3MBTL1MAPTDPP4 | |
| SCHEMBL10118344 | 0.81 | RAB9A (0.43) | RAB9APOLBL3MBTL1ACEREN | |
| SCHEMBL10118348 | 0.81 | NPC1 (0.39) | RAB9APOLBL3MBTL1ACEREN | |
| SCHEMBL16790988 | 0.81 | JAK3 (0.41) | RAB9APOLBL3MBTL1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2023-02-16 | — | — | US | disclosed |
| US-10646463-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170258925-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9585909-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258925-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | RAB9A 1490/4885POLB 1365/4885L3MBTL1 1118/4885 |
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | METAP2, ADIPOR2, METAP1 | RAB9A 2446/4885POLB 3632/4885L3MBTL1 2313/4885 |
| US-10646463-B2 | Treatment for tumors driven by metabolic dysfunction | PCK2, GOT2, PC | RAB9A 2174/4885POLB 1039/4885L3MBTL1 1272/4885 |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | RAB9A 2446/4885POLB 3632/4885L3MBTL1 2313/4885 |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | RAB9A 2446/4885POLB 3632/4885L3MBTL1 2313/4885 |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | PCK2, GOT2, PC | RAB9A 2174/4885POLB 1039/4885L3MBTL1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.